|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-3-31
|
|
pubmed:abstractText |
Interleukin-2 (IL-2) shows encouraging clinical results in metastatic renal cell carcinoma (RCC) patients, but is limited by substantial toxicity. Cell-based therapy holds a promise, but past attempts in RCC were unsuccessful. Advances in tumor-infiltrating lymphocytes (TIL) generation technology and modified clinical protocols recently yielded a 50% response in refractory melanoma patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
pubmed-author:BesserMichal JMJ,
pubmed-author:Cohen-SinaiTaliT,
pubmed-author:DotanZoharZ,
pubmed-author:FridmanEduardE,
pubmed-author:ItzhakiOritO,
pubmed-author:KeisariYonaY,
pubmed-author:MarkelGalG,
pubmed-author:OvedKfirK,
pubmed-author:RamonJacobJ,
pubmed-author:SchachterJacobJ,
pubmed-author:SeidmanRachelR,
pubmed-author:TrevesAvraham JAJ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
145-54
|
|
pubmed:meshHeading |
pubmed-meshheading:19331144-CD4-CD8 Ratio,
pubmed-meshheading:19331144-Carcinoma, Renal Cell,
pubmed-meshheading:19331144-Humans,
pubmed-meshheading:19331144-Immunotherapy, Adoptive,
pubmed-meshheading:19331144-Kidney Neoplasms,
pubmed-meshheading:19331144-Lymphocytes, Tumor-Infiltrating,
pubmed-meshheading:19331144-Neoplasm Staging,
pubmed-meshheading:19331144-T-Lymphocytes
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma.
|
|
pubmed:affiliation |
Ella Institute of Melanoma, Sheba Cancer Research Center, Israel.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
